StemCyte is an international biopharmaceutical company focused on cord blood banking and the development of cell-therapy biologics. Founded in the United States in 1997, the company has established a strong presence in Taiwan and India. To date, StemCyte has built a public cord blood inventory of more than 36,000 publicly donated cord blood units (CBUs), making it among the world’s largest with broad HLA/ethnic diversity and rigorous quality standards. It is also one of the few biotechnology companies that operate both public and private cord blood banks.

Over the past two decades, StemCyte has released more than 2,300 CBUs for transplantation to 350+ transplant centers worldwide, supporting the treatment of a wide range of diseases. In November 2024, the company became the world’s first private enterprise to receive U.S. FDA approval of its Biologics License Application (BLA) for REGENECYTE, an important milestone for cord-blood–derived therapies.

In collaboration with leading medical teams domestically and internationally, StemCyte continues to advance cell-therapy R&D. The company is actively developing allogeneic cord-blood–derived treatments for conditions such as long COVID and acute ischemic stroke. These programs have shown meaningful clinical progress, and StemCyte remains committed to expanding into multiple therapeutic indications.